Hyper Ice v. Therabody: Three-Patent Percussive & Facial Device Dispute Consolidated in 92 Days
Hyper Ice, Inc. asserted three patents covering percussive therapy and facial recovery devices against rival Therabody, Inc. and its TheraFace Bundle and Theragun PRO Plus products. The California Central District Court consolidated this case into a lead docket after just 92 days, setting up a unified Markman hearing across related proceedings.
Rival recovery device makers clash over facial and percussive therapy IP
Hyper Ice, Inc. filed suit against Therabody, Inc. on 19 September 2024 in the California Central District Court, asserting infringement of three US patents — US11938082B1, US12036174B1, and US11857482B1 — covering percussive therapy and facial recovery device technology. The accused products are Therabody’s TheraFace Bundle (comprising the TheraFace PRO with Hot and Cold Rings) and the Theragun PRO Plus, both flagship consumer wellness devices sold in direct competition with Hyper Ice’s product lines.
The case was administratively closed on 20 December 2024 following a court order consolidating it into lead Case No. 8:24-cv-01472-JWH-DFM for pretrial purposes through the Markman hearing. The court simultaneously set a claim construction schedule specific to US12036174B1 and indicated a separate trial scheduling order would follow the claim construction process. Consolidation here is a procedural mechanism — not a merits disposition — that centralises overlapping patent disputes before a single judge to avoid duplicative proceedings.
The 92-day timeline to administrative closure reflects the court’s efficiency in identifying related cases and consolidating them early, which is consistent with California Central District practice for multi-case patent portfolios. The substantive litigation — including Markman hearings, claim construction, and ultimately trial — will continue under the lead docket. What remains unknown from the public record is the full scope of overlapping claim charts and whether any settlement discussions are underway, given the court’s invitation to contact the Magistrate Judge for a settlement conference.
Filing to Case Consolidated in 92 days
92 days to administrative close — consolidation resolved faster than most district court stays
Case consolidated: what the court’s order means for both parties
Consolidation is procedural — not a win or loss on the merits
The court’s order to administratively close this case and consolidate it into Case No. 8:24-cv-01472 is a docket management tool, not a substantive ruling. All claims, counterclaims, and patent assertions survive and will proceed under the lead case. Either party may move to sever at any time for good cause, preserving tactical flexibility.
No merits adjudicationHyper Ice retains all patent claims in the consolidated proceeding
Hyper Ice’s infringement assertions across all three patents remain live. Consolidation into a single Markman proceeding may benefit the plaintiff by presenting a unified claim construction narrative across US11938082B1, US12036174B1, and US11857482B1. However, it also exposes each patent to coordinated challenge across related cases simultaneously.
Claims intactTherabody faces coordinated multi-patent pressure under one judge
Consolidation concentrates the litigation risk for Therabody — the TheraFace Bundle and Theragun PRO Plus now face scrutiny alongside any related accused products in the lead case. A unified Markman hearing may limit Therabody’s ability to run divergent invalidity or non-infringement arguments across separate proceedings, typically increasing settlement leverage for the patentee.
Coordinated exposureMulti-patent consolidation raises the stakes for percussive wellness IP
Three overlapping patents asserted against two flagship product lines in a single consolidated proceeding signals that Hyper Ice is pursuing a portfolio enforcement strategy. For the broader consumer wellness and percussive therapy sector, this consolidation pattern — particularly around facial recovery devices — suggests intensifying IP enforcement as the category matures and product differentiation narrows.
Portfolio enforcement signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Hyper Ice, Inc. | Company | Consumer recovery technology company — holder of US11938082B1, US12036174B1, US11857482B1Search in Eureka ↗ |
| Defendant | Therabody, Inc. | Company | Therabody, Inc. — maker of TheraFace Bundle and Theragun PRO Plus percussive wellness devicesSearch in Eureka ↗ |
| Plaintiff counsel | Benjamin A. Herbert | Attorney | Counsel for Hyper Ice, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lawrence Robert LaPorte | Attorney | Counsel for Hyper Ice, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Lewis Brisbois Bisgaard & Smith LLP | Law Firm | Representing Hyper Ice, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Miller Barondess, LLP | Law Firm | Representing Hyper Ice, Inc.Search in Eureka ↗ |
| Defendant counsel | Bradley Michael Berg | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Brett J. Williamson | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Cameron W. Westin | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant counsel | Marc J. Pensabene | Attorney | Counsel for Therabody, Inc.Search in Eureka ↗ |
| Defendant law firm | O’melveney & Myers LLP | Law Firm | Representing Therabody, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Central District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a purely administrative disposition: this case carries no finding of infringement, validity, or damages. The direction to close the case ‘administratively’ while all claims remain active in the lead docket is standard practice when related patent cases share common parties and overlapping claim sets. The explicit reservation of each party’s right to move for severance indicates the consolidation is provisional and tactically reversible — a nuance that both Hyper Ice and Therabody will monitor as the Markman process develops.
US11938082B1, US12036174B1 & US11857482B1 — Percussive & Facial Recovery Device Patents
The three patents at issue — US11938082B1, US12036174B1, and US11857482B1 — appear to cover percussive therapy devices and facial recovery technology, including thermal treatment accessories such as hot and cold rings. These are utility patents filed on US application numbers 18/515112, 18/526980, and 17/681367 respectively, suggesting relatively recent prosecution timelines consistent with the fast-moving consumer wellness hardware sector. The patents’ grant dates and application numbers suggest Hyper Ice has been actively building patent coverage in parallel with product development.
Strategically, a three-patent portfolio asserted against two of Therabody’s most commercially prominent products — the TheraFace PRO bundle and the Theragun PRO Plus — indicates Hyper Ice is seeking to establish IP barriers across both the percussive massage and facial recovery subcategories simultaneously. For competitors and new entrants in the recovery device space, these patents represent a potential enforcement perimeter around core product architectures. The outcome of claim construction in the lead docket will determine how broadly or narrowly each patent reads on competing product designs.
Should your product team run an FTO against US11938082B1, US12036174B1 & US11857482B1?
Any company developing percussive therapy devices, facial recovery hardware, or thermal accessory products for the consumer wellness market should treat this consolidated litigation as a direct FTO signal. Hyper Ice’s willingness to assert three patents simultaneously against Therabody’s flagship SKUs — including the TheraFace Hot and Cold Ring accessory system — suggests active enforcement intent across the category, not a single-product dispute.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim scope of US11938082B1, US12036174B1, and US11857482B1, identify prior art that may narrow those claims, and flag design-around opportunities before the Markman ruling crystalises the enforceable claim boundaries. Running this analysis now — before claim construction — gives your team the maximum range of design options.
Run a freedom-to-operate analysis on US11938082B1 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases in percussive therapy and consumer wellness devices
Related patent disputes involving percussive therapy, facial recovery, and consumer wellness hardware litigated in the California Central District Court.
What this case signals for the consumer wellness device IP landscape
A three-patent consolidation between the two dominant percussive therapy brands marks a significant escalation in recovery device IP enforcement.
Portfolio consolidation signals a shift from single-patent to multi-front enforcement
Hyper Ice’s assertion of three patents across two flagship Therabody products — coordinated enough to trigger judicial consolidation — is consistent with a deliberate portfolio enforcement strategy. Companies operating in the percussive therapy and facial recovery device space should audit their own product lines against Hyper Ice’s growing patent portfolio.
Claim construction will be the decisive battleground in the lead docket
The court set a specific claim construction schedule for US12036174B1, suggesting this patent is the contested anchor of the dispute. How the Markman hearing resolves the scope of facial device recovery claims will set precedent affecting every competitor in this category — not just Therabody.
Hyper v Therabody — key questions answered
Consolidation means Case No. 8:24-cv-02034 has been administratively closed and merged into lead Case No. 8:24-cv-01472-JWH-DFM for pretrial purposes. All patent claims survive and will be heard together through the Markman hearing. No merits ruling has been made.
Hyper Ice asserted three patents: US11938082B1 (application 18/515112), US12036174B1 (application 18/526980), and US11857482B1 (application 17/681367), covering percussive therapy and facial recovery device technology against the TheraFace Bundle and Theragun PRO Plus.
The accused products are Therabody’s TheraFace Bundle — comprising the TheraFace PRO with TheraFace Hot and Cold Rings — and the Theragun PRO Plus, both flagship consumer recovery devices sold in direct competition with Hyper Ice’s product range.
The court specifically set a claim construction schedule for US12036174B1, indicating this patent is a contested focal point. The Markman ruling will define the enforceable scope of the asserted claims across all three patents and will materially influence infringement and invalidity positions for both parties in the lead docket.
Yes. The court’s consolidation order explicitly states that any party may move to sever the cases at any time for good cause shown. This means the consolidation is provisional and either party retains the right to seek separate proceedings if strategic circumstances change.
PatSnap Eureka searches patents and litigation data to answer instantly.